WallStreetZenWallStreetZen

NASDAQ: TARA
Protara Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for TARA

Based on 2 analysts offering 12 month price targets for Protara Therapeutics Inc.
Min Forecast
$23.00+644.34%
Avg Forecast
$26.50+757.61%
Max Forecast
$30.00+870.87%

Should I buy or sell TARA stock?

Based on 2 analysts offering ratings for Protara Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TARA stock forecasts and price targets.

TARA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-06
lockedlocked$00.00+00.00%2024-04-22

1 of 1

Forecast return on equity

Is TARA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.39%

Forecast return on assets

Is TARA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

TARA revenue forecast

What is TARA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$34.6M
Avg 2 year Forecast
$15.4M
Avg 3 year Forecast
$22.6M

TARA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TARA$3.09$26.50+757.61%Buy
MURA$3.76$13.00+245.74%Strong Buy
CSBR$4.70N/AN/A
AVRO$1.39$2.00+43.88%Hold
LTRN$6.03N/AN/A

Protara Therapeutics Stock Forecast FAQ

Is Protara Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TARA) stock is to Buy TARA stock.

Out of 2 analysts, 0 (0%) are recommending TARA as a Strong Buy, 2 (100%) are recommending TARA as a Buy, 0 (0%) are recommending TARA as a Hold, 0 (0%) are recommending TARA as a Sell, and 0 (0%) are recommending TARA as a Strong Sell.

If you're new to stock investing, here's how to buy Protara Therapeutics stock.

What is TARA's revenue growth forecast for 2025-2027?

(NASDAQ: TARA) Protara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Protara Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TARA's revenue for 2025 to be $712,413,170, with the lowest TARA revenue forecast at $712,413,170, and the highest TARA revenue forecast at $712,413,170. On average, 1 Wall Street analysts forecast TARA's revenue for 2026 to be $317,085,630, with the lowest TARA revenue forecast at $317,085,630, and the highest TARA revenue forecast at $317,085,630.

In 2027, TARA is forecast to generate $465,230,508 in revenue, with the lowest revenue forecast at $144,129,832 and the highest revenue forecast at $786,331,183.

What is TARA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TARA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is TARA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TARA price target, the average TARA price target is $26.50, with the highest TARA stock price forecast at $30.00 and the lowest TARA stock price forecast at $23.00.

On average, Wall Street analysts predict that Protara Therapeutics's share price could reach $26.50 by May 6, 2025. The average Protara Therapeutics stock price prediction forecasts a potential upside of 757.61% from the current TARA share price of $3.09.

What is TARA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TARA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.